10:03 AM EDT, 07/08/2025 (MT Newswires) -- Niagen Bioscience ( NAGE ) said Tuesday it has signed an agreement with Norway's Haukeland University Hospital, securing exclusive rights to a body of proprietary intellectual property and data to develop its nicotinamide adenine dinucleotide coenzyme, or NAD+, patented as Nicotinamide Riboside, and branded as Niagen, as a potential therapy for Parkinson's Disease.

NAD+ is a coenzyme found in every cell of the human body, Niagen said, adding that NAD+ depletion is a key contributor to age-related changes in health and vitality. Niagen is the company's exclusive, patent-protected form of NAD+.

Central to the agreement is access to findings from the NOPARK trial, a randomized, double-blind, placebo-controlled phase 3 investigation of NAD+ augmentation in persons with early Parkinson's Disease to date. The study was completed in June and is expected to be published by the end of 2025, the company said.

The data is expected to support future regulatory filings for Conditional Marketing Authorization, Accelerated Approval, and Marketing Authorization under the European Medicines Agency guidelines for the potential treatment of Parkinson's Disease, the company said.

Price: 12.40, Change: -0.04, Percent Change: -0.32